Moe Alsumidaie: Mitapivat Challenges the Transfusion-Centric Model of Thalassaemia Care
Moe Alsumidaie, Chief Editor at The Clinical Trial Vanguard, Head of Research at CliniBiz, shared a post on LinkedIn:
“For decades, thalassaemia meant one thing for patients: a transfusion appointment every three to four weeks, year after year, for life.
That schedule just got its first real challenger.
Agios Pharmaceuticals built the ENERGIZE-T Phase 3 trial around a single question: can one twice-daily oral tablet meaningfully reduce how often patients need someone else’s blood to survive?
Across 258 patients, 48 weeks of blinded treatment, and both alpha and beta thalassaemia, the answer was yes.
The FDA agreed, approving mitapivat in December 2025 as the first oral treatment for anemia in adults with beta-thalassaemia and the first drug approval of any kind for adults with alpha-thalassaemia.
The part the headline misses: the trial’s design is the real story.
Agios chose transfusion burden reduction as the primary endpoint, not hemoglobin response, not a surrogate.
That is a harder target, and the FDA accepting it signals something bigger for the field.
Any sponsor now running a chronic transfusion program will face a benchmark of 258 patients and 48 weeks of clean data.
A shorter trial will need a pre-negotiated justification.
The bar moved on December 23, 2025, and it is not moving back.
The economics make this urgent.
Annual healthcare costs for transfusion-dependent thalassaemia patients in the U.S. run over 137,000 dollars per patient.
A therapy that compresses transfusion frequency compresses those cost curves for decades.
Are we building enough health economics evidence into rare disease Phase 3 designs from the start, or are we still treating it as a post-approval problem?”
Stay updated with Hemostasis Today.
-
Sep 15, 2026, 15:29Abdul Muqtadir Abbasi: Recognizing Thalassemia Trait Is Essential for Every Physician
-
Sep 15, 2026, 15:17Shehab Mohamed: A New Regional Consensus on HLH Diagnosis and Management
-
Sep 15, 2026, 15:17Sheharyar Raza: Managing Randomness in Artificial Intelligence for Transfusion Medicine
-
Sep 15, 2026, 15:00Sarah Wachtman: Modeling AAV-Based Gene Therapy for Hemophilia A Using Pediatric Liver Organoids
-
Sep 15, 2026, 15:00Ashenafi Tazebew Amare: From Blood Donation to Innovation and Patient Access
-
Sep 15, 2026, 14:56Glanzmann Thrombasthenia Beyond Platelet Transfusion
-
Sep 15, 2026, 14:55Christina Pohlman: The Hidden Complexity of Warfarin Therapy in APS
-
Sep 15, 2026, 14:44Consuela A. Albright: Building a More Connected Sickle Cell Care System
-
Sep 15, 2026, 14:43Andrew Jackson: Cyanosis as a Clue to Central Venous Obstruction